Clinical research organization PRA has opened a second office in China to house its continued expansion in China and the Asia Pacific region.
The new Beijing facility is expected to enhance PRA local project teams' ability in meeting the growing demand for its clinical drug development programs and also to collocate them with many of their key Beijing clients.
PRA established its first China office in 2005 in Shanghai and has been operating it for over 10 years.
PRA Asia Pacific, Middle East and North Africa clinical operations regional director Helen Neal said the company is striving to strengthen its existing operations in China and the Asia Pacific region in view of the increasing demand for clinical sites in Asia.
"By adding more professional staff and locations, we can give our clients greater access to these critical markets and geography,'' Neal added.
''In addition to our expansion in China, we continue to increase our presence into new and emerging Southeast Asian regions for access to patients and resources."
PRA scientific and medical Affairs executive vice president Kent Thoelke said in order for global drug development to continue successfully, the need to access patients at high-quality ICH/GCP sites in emerging regions like China is critical.
''PRA's expansion in this market gives us the ability to bring exciting new clinical trials to a much broader market in China, while providing even greater patient access to our clients and sponsor companies," Thoelke added.
